Literature DB >> 8219020

[3H]-GR113808 labels 5-HT4 receptors in the human and guinea-pig brain.

C Waeber1, M Sebben, C Grossman, F Javoy-Agid, J Bockaert, A Dumuis.   

Abstract

A tritiated specific and highly potent 5-HT4 antagonist: [3H]-GR113808 was used to label specific binding sites in human brain and for comparison in guinea-pig brain. [3H]-GR113808 association and dissociation were rapid, the binding was saturable and displaced by various serotoninergic agents with an affinity corresponding to their previously reported 5-HT4 receptor mediated effects. In vitro ligand binding autoradiography was used to investigate the distribution of [3H]-GR113808 recognition sites on human brain sections. The highest density was observed in the striato-nigral system. Low densities of binding sites were also found in hippocampus, neocortex and colliculus. This distribution of [3H]-GR113808 binding sites is similar to that found in the guinea-pig brain.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8219020     DOI: 10.1097/00001756-199309000-00007

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  15 in total

1.  Isolation of the serotoninergic 5-HT4(e) receptor from human heart and comparative analysis of its pharmacological profile in C6-glial and CHO cell lines.

Authors:  J Mialet; I Berque-Bestel; P Eftekhari; M Gastineau; M Giner; Y Dahmoune; P Donzeau-Gouge; J Hoebeke; M Langlois; S Sicsic; R Fischmeister; F Lezoualc'h
Journal:  Br J Pharmacol       Date:  2000-02       Impact factor: 8.739

2.  Pharmacological characterization of the human 5-HT(4(d)) receptor splice variant stably expressed in Chinese hamster ovary cells.

Authors:  J Mialet; I Berque-Bestel; S Sicsic; M Langlois; R Fischmeister; F Lezoualc'h
Journal:  Br J Pharmacol       Date:  2000-10       Impact factor: 8.739

3.  Transient paroxysmal dystonia in an infant possibly induced by cisapride.

Authors:  L Angelini; G Zorzi; V Rumi; N Nardocci; T Mennini
Journal:  Ital J Neurol Sci       Date:  1996-04

Review 4.  Therapeutics of Neurotransmitters in Alzheimer's Disease.

Authors:  Ramesh Kandimalla; P Hemachandra Reddy
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

5.  Visceral analgesic effect of 5-HT(4) receptor agonist in rats involves the rostroventral medulla (RVM).

Authors:  Jyoti N Sengupta; Aaron Mickle; Pradeep Kannampalli; Russell Spruell; John McRorie; Reza Shaker; Adrian Miranda
Journal:  Neuropharmacology       Date:  2013-12-12       Impact factor: 5.250

6.  5-HT receptors in mammalian brain: receptor autoradiography and in situ hybridization studies of new ligands and newly identified receptors.

Authors:  G Mengod; M T Vilaró; A Raurich; J F López-Giménez; R Cortés; J M Palacios
Journal:  Histochem J       Date:  1996-11

Review 7.  Role of the serotonergic system in the neurobiology of alcoholism: implications for treatment.

Authors:  Bankole A Johnson
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

Review 8.  Serotonin 1A and Serotonin 4 Receptors: Essential Mediators of the Neurogenic and Behavioral Actions of Antidepressants.

Authors:  Benjamin Adam Samuels; Indira Mendez-David; Charlène Faye; Sylvain André David; Kerri A Pierz; Alain M Gardier; René Hen; Denis J David
Journal:  Neuroscientist       Date:  2014-12-08       Impact factor: 7.519

9.  Ability of 5-HT4 receptor ligands to modulate rat striatal dopamine release in vitro and in vivo.

Authors:  L J Steward; J Ge; R L Stowe; D C Brown; R K Bruton; P R Stokes; N M Barnes
Journal:  Br J Pharmacol       Date:  1996-01       Impact factor: 8.739

10.  Radioiodinated SB 207710 as a radioligand in vivo: imaging of brain 5-HT4 receptors with SPET.

Authors:  Victor W Pike; Christer Halldin; Kenji Nobuhara; Julka Hiltunen; Rachel S Mulligan; Carl-Gunnar Swahn; Per Karlsson; Hans Olsson; Susan P Hume; Ella Hirani; Jaqueline Whalley; Lyn S Pilowsky; Stig Larsson; Per-Olof Schnell; Peter J Ell; Lars Farde
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-09-23       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.